A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF TILREKIMIG IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Pfizer
Summary
A Continuation Study of Tilrekimig in Adults with Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About this Medicine when Used for a Long Period of Time.
Description
C4531015 is a multicenter, open-label extension study designed to evaluate the longer-term safety and tolerability of tilrekimig in eligible participants with chronic obstructive pulmonary disease (COPD) who have participated in and completed the applicable requirements of the parent study, C4531031. Participants who complete the protocol-defined parent-study period may be considered for enrollment in C4531015. Before entering the extension study, participants must provide informed consent, satisfy all C4531015 eligibility criteria, and be considered appropriate for continued study treatment…
Eligibility
- Age range
- 35–80 years
- Sex
- All
- Healthy volunteers
- No
INCLUSION CRITERIA * Participants who completed parent study C4531031. * Individuals of childbearing potential must be willing to use a highly effective method of contraception. EXCLUSION CRITERIA * Ongoing safety-significant AE. * Parent-study SAE incompatible with continued participation. * Medical, laboratory, psychiatric, or behavioral condition that increases risk or interferes with study participation. * Pregnancy or breastfeeding.
Interventions
- DrugTilrekimig
SC injection
Locations (3)
- Institute of HealthCare Assessment d/b/a Apex Clinical ResearchSan Diego, California
- Southeastern Research CenterWinston-Salem, North Carolina
- Clinical Research Associates of Central PADuBois, Pennsylvania